Iacobellis Gianluca
Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL, USA.
Curr Opin Pharmacol. 2016 Apr;27:13-8. doi: 10.1016/j.coph.2016.01.004. Epub 2016 Feb 2.
Epicardial fat is the visceral fat depot of the heart. Given its rapid metabolism, organ fat specificity and simple objective measurability, epicardial fat can serve as target for pharmaceutical agents targeting the adipose tissue. Epicardial fat has shown to significantly respond to thiazolidinediones, glucagon like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors and statins. Epicardial fat may represent a measurable risk factor and modifiable therapeutic target. Targeted pharmaceutical interventions may allow the epicardial fat to resume its physiological role. A drug-induced browning effect on epicardial fat suggests the development of pharmacological strategies to increase energy consumption. The potential of modulating the epicardial fat transcriptome with targeted pharmacological agents can open new avenues in the pharmacotherapy of cardio-metabolic diseases.
心外膜脂肪是心脏的内脏脂肪库。鉴于其快速代谢、器官脂肪特异性和简单的客观可测量性，心外膜脂肪可作为针对脂肪组织的药物靶点。心外膜脂肪已显示出对噻唑烷二酮类药物、胰高血糖素样肽1受体激动剂、二肽基肽酶-4抑制剂和他汀类药物有显著反应。心外膜脂肪可能是一个可测量的危险因素和可调节的治疗靶点。有针对性的药物干预可能使心外膜脂肪恢复其生理作用。药物诱导的心外膜脂肪褐变效应提示了开发增加能量消耗的药理学策略。用有针对性的药物调节心外膜脂肪转录组的潜力可为心脏代谢疾病的药物治疗开辟新途径。
